Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-fluorouracil + calcipotriol versus 5-fluorouracil for actinic keratosis
NL-OMON60668Phase 4Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of calcipotriol and fluorouracil in actinic keratosis (AK), sponsored by Maastricht University Medical Center+. Primary endpoint: Treatment success at 12 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
calcipotriolfluorouracil
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NL-OMON60668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60668.